| |
Lipocalin-2 (ng/ml)
|
MMP-9 (ng/ml)
|
|---|
| |
t1
|
t2
|
t3
| | | | |
P
trend
a
|
|---|
| |
(2.63-59.03)
|
(59.03-109.65)
|
(109.65-772.34)
| |
(0.15-34.42)
|
(34.42-80.36)
|
(80.36-397.09)
|
|---|
|
Age, mean (SD)
|
46.5 (11.6)
|
47.3 (10.6)
|
45.9 (9.9)
|
0.67b
|
48.2 (10.5)
|
44.4 (9.8)
|
47.1 (11.5)
|
0.58b
|
|
Premenopausal status, %
|
65.0
|
60.4
|
64.4
|
0.93
|
53.0
|
72.6
|
64.0
|
0.11
|
|
BMI < 25 kg/m2, %
|
82.0
|
74.5
|
70.3
|
0.05
|
77.0
|
78.4
|
71.3
|
0.35
|
|
TNM stage, %
|
|
I
|
32.0
|
40.2
|
41.6
|
0.59
|
35.0
|
46.1
|
32.7
|
0.72
|
|
IIA –IIB
|
48.0
|
39.2
|
34.7
| |
39.0
|
35.3
|
47.5
| |
|
IIIA –IIIC
|
20.0
|
20.6
|
23.8
| |
26.0
|
18.6
|
19.8
| |
|
Tumor size < 2cm, %
|
46.0
|
53.9
|
57.4
|
0.11
|
47.0
|
62.8
|
47.5
|
0.95
|
|
Lymph-node negative, %
|
57.0
|
54.9
|
56.4
|
0.94
|
55.0
|
60.8
|
52.5
|
0.72
|
|
Histologic grade I-II, %
|
48.9
|
61.2
|
55.7
|
0.36
|
48.4
|
62.2
|
55.2
|
0.35
|
|
Nuclear grade I-II, %
|
51.6
|
58.0
|
54.1
|
0.73
|
52.1
|
57.0
|
54.6
|
0.72
|
|
ER positive, %
|
56.0
|
59.8
|
55.5
|
0.94
|
53.0
|
61.8
|
56.4
|
0.63
|
|
PR positive, %
|
51.0
|
54.9
|
51.5
|
0.95
|
48.0
|
58.8
|
50.5
|
0.73
|
|
Adjuvant chemotherapy Yes, %
|
75.8
|
66.7
|
75.8
|
0.99
|
74.2
|
70.0
|
74.0
|
0.98
|
|
Radiation therapy Yes, %
|
62.2
|
58.0
|
65.0
|
0.69
|
67.7
|
60.6
|
57.0
|
0.12
|
|
Hormone receptor therapy Yes, %
|
63.6
|
69.0
|
66.0
|
0.73
|
62.6
|
70.0
|
66.0
|
0.61
|
-
a Mantel-Haenszel chi-square test.
-
b Pearson correlation coefficients test.
